Transthyretin (TTR) Related Amyeloidosis (ATTR) Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Transthyretin (TTR) Related Amyeloidosis Pipeline Analysis report covers 11 drugs currently in different phases of development. Transthyretin (TTR) Related Amyeloidosis or ATTR is a rare, progressive condition characterized by abnormal buildup of amyloid protein in different tissues and organs of the body. The disease is caused by misfolding of the transthyretin (TTR) protein and is secondary transporter of thyroxine and retinol-binding protein. The disease is classified into 3 types: Familial Amyloid Polyneuropathy (TTR-FAP), Familial Amyloid Cardiomyopathy (TTR-FAC) and Senile Systemic Amyloidosis (SSA). TTR-FAP and TTR-FAC are both inherited type of Transthyretin (TTR) Related Amyeloidosis while SSA is acquired during the lifetime of the individual.
The report provides Transthyretin (TTR) Related Amyeloidosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pfizer, Proclara Biosciences and SOM Biotech among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration